Free tool
FAERS Monitor: Herceptin Hylecta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761106 or its brand name (Herceptin Hylecta, Trastuzumab and Hyaluronidase-Oysk). Reports on generic versions are filed under their own applications.
Reports
107
Serious
25
23% of reports
Hospitalization
6
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event30
- off label use23
- injection site pain8
- diarrhoea7
- product storage error7
- nausea6
- pain6
- neuropathy peripheral5
- death4
- fatigue4
- intentional product use issue4
- product administered at inappropriate site4
- stomatitis4
- weight decreased4
- alopecia3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 6 |
| 2020 | 12 |
| 2021 | 16 |
| 2022 | 17 |
| 2023 | 9 |
| 2024 | 21 |
| 2025 | 15 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,052 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administered at inappropriate siteSignal | 4 | 42.9 | 16.4 | 125 |
| no adverse eventSignal | 30 | 32.6 | 24.0 | 894 |
| product storage errorSignal | 7 | 15.7 | 7.7 | 83 |
| stomatitisSignal | 4 | 13.0 | 5.0 | 33 |
| neuropathy peripheralSignal | 5 | 10.3 | 4.4 | 33 |
| intentional product use issueSignal | 4 | 9.0 | 3.4 | 21 |
| off label useSignal | 23 | 5.2 | 3.6 | 76 |
| injection site painSignal | 8 | 5.1 | 2.6 | 23 |
| alopecia | 3 | 3.0 | 1.0 | 2 |
| weight decreased | 4 | 2.8 | 1.1 | 3 |
| diarrhoea | 7 | 2.1 | 1.0 | 3 |
| pain | 6 | 1.9 | 0.9 | 2 |
| nausea | 6 | 1.5 | 0.7 | 1 |
| fatigue | 4 | 1.0 | 0.4 | 0 |
| death | 4 | 0.9 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.